Multi-centric study to contain antimicrobial resistant neonatal sepsis begins in India
An international clinical trial named NeoSep1 has expanded to India to test new antibiotic combinations for treating neonatal sepsis. The study aims to address the growing threat of antimicrobial resistance in newborns across Asia and Africa.
Why it matters
Neonatal sepsis is a leading cause of infant mortality, and finding effective antibiotic treatments is critical as existing drugs become increasingly ineffective against resistant infections.
Striking at the heart of antimicrobial resistance, the international NeoSep 1 trial to evaluate life-saving antibiotic combinations for newborns with sepsis has expanded to India, with the first baby being recruited at the Jawaharlal Postgraduate Education Institute of Medical and Research (JIPMER) in Puducherry.
This was followed by recruiting an infant for the study in Pt. B.D. Sharma PGIMS in Rohtak. The next on the list is Lokmanya Tilak Municipal College and General Hospital, Mumbai. Globally, the study, sponsored by the GARDP Foundation in collaboration with the UCL Innovative Clinical Trials Unit; City St George’s, University of London (SGUL), and Penta Foundation, is also underway in Vietnam and Pakistan, and will soon start in Malaysia, Bangladesh and Uganda.
According to a GARDP statement, NeoSep1 aims to enrol 3,000 newborns across Asia and Africa by the end of 2028. Earlier, newborns were enrolled in Ghana, Kenya and South Africa.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in